Tags: icahn | amylin | drug | pharma | M&A

Icahn: Amylin Should Put Itself Up for Sale

Tuesday, 03 Apr 2012 07:12 PM

Amylin Pharmaceuticals Inc., which turned down a $22-a-share bid from Bristol-Myers Squibb Co. earlier this year, should pursue a sale process to get the best price for shareholders, investor Carl Icahn said.

“This company could fetch more than $22,” Icahn, who is San Diego-based Amylin’s third-largest stockholder with 14.4 million shares as of Dec. 31, said in a telephone interview today. “The company should go through a process and try to get the price they can for shareholders, and let the shareholders decide.”

© Copyright 2015 Bloomberg News. All rights reserved.

1Like our page
2Share
83
2012-12-03
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved